Literature DB >> 25331694

Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.

Shashank Gupta1, Sandeep Tyagi2, William R Bishai3.   

Abstract

Bedaquiline is a newly approved drug for the treatment of multidrug-resistant tuberculosis, but there are concerns about its safety in humans. We found that the coadministration of verapamil with subinhibitory doses of bedaquiline gave the same bactericidal effect in mice as did the full human bioequivalent bedaquiline dosing. Adding verapamil to bedaquiline monotherapy also protected against the development of resistant mutants in vivo. The adjunctive use of verapamil may permit use of lower doses of bedaquiline to be used and thereby reduce its dose-related toxicities in tuberculosis patients.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25331694      PMCID： PMC4291418          DOI： 10.1128/AAC.04019-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis.

Authors:  Shashank Gupta; Keira A Cohen; Kathryn Winglee; Mamoudou Maiga; Bassirou Diarra; William R Bishai
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

2.  Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.

Authors:  Shashank Gupta; Sandeep Tyagi; Deepak V Almeida; Mariama C Maiga; Nicole C Ammerman; William R Bishai
Journal:  Am J Respir Crit Care Med       Date:  2013-09-01       Impact factor: 21.405

3.  The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities.

Authors:  Laia Ruiz Mingote; Dorothy Namutamba; Francis Apina; Nomampondo Barnabas; Carmen Contreras; Taharqa Elnour; Mike Watson Frick; Cynthia Lee; Barbara Seaworth; Debra Shelly; Natalie Skipper; Ezio Tavora dos Santos Filho
Journal:  Lancet       Date:  2014-07-10       Impact factor: 79.321

4.  Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Authors:  A H Diacon; P R Donald; A Pym; M Grobusch; R F Patientia; R Mahanyele; N Bantubani; R Narasimooloo; T De Marez; R van Heeswijk; N Lounis; P Meyvisch; K Andries; D F McNeeley
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

Review 5.  Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis.

Authors:  Pedro Eduardo Almeida da Silva; Andrea Von Groll; Anandi Martin; Juan Carlos Palomino
Journal:  FEMS Immunol Med Microbiol       Date:  2011-07-04

6.  Systemic availability of oral verapamil and effect on PR interval in man.

Authors:  A Johnston; C D Burgess; J Hamer
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

7.  Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism.

Authors:  Kristin N Adams; Kevin Takaki; Lynn E Connolly; Heather Wiedenhoft; Kathryn Winglee; Olivier Humbert; Paul H Edelstein; Christine L Cosma; Lalita Ramakrishnan
Journal:  Cell       Date:  2011-03-03       Impact factor: 41.582

8.  Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action.

Authors:  A Oros; M J Houtman; P Neco; A M Gomez; S Rajamani; P Oosterhoff; N J Attevelt; J D Beekman; M A G van der Heyden; L Ver Donck; L Belardinelli; S Richard; G Antoons; M A Vos
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

9.  Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis.

Authors:  Andreas H Diacon; Rodney Dawson; Florian Von Groote-Bidlingmaier; Gregory Symons; Amour Venter; Peter R Donald; Almari Conradie; Ngozi Erondu; Ann M Ginsberg; Erica Egizi; Helen Winter; Piet Becker; Carl M Mendel
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  Acquired resistance of Mycobacterium tuberculosis to bedaquiline.

Authors:  Koen Andries; Cristina Villellas; Nele Coeck; Kim Thys; Tom Gevers; Luc Vranckx; Nacer Lounis; Bouke C de Jong; Anil Koul
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240
View more
  20 in total

1.  Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish.

Authors:  Christian Dupont; Albertus Viljoen; Sangeeta Thomas; Françoise Roquet-Banères; Jean-Louis Herrmann; Kevin Pethe; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

2.  A Protein Complex from Human Milk Enhances the Activity of Antibiotics and Drugs against Mycobacterium tuberculosis.

Authors:  Virginia Meikle; Ann-Kristin Mossberg; Avishek Mitra; Anders P Hakansson; Michael Niederweis
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 3.  Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

Authors:  Adetomiwa A Adeniji; Kirsten E Knoll; Du Toit Loots
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-05       Impact factor: 4.813

4.  Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.

Authors:  Jian Xu; Rokeya Tasneen; Charles A Peloquin; Deepak V Almeida; Si-Yang Li; Kala Barnes-Boyle; Yu Lu; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 5.  Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?

Authors:  Stephen K Field
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

6.  Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.

Authors:  Elise D Pieterman; Lindsey H M Te Brake; Gerjo J de Knegt; Aart van der Meijden; Jan-Willem C Alffenaar; Hannelore I Bax; Rob E Aarnoutse; Jurriaan E M de Steenwinkel
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

7.  Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance.

Authors:  Luke Bown; Santosh K Srivastava; Brandon M Piercey; Clarissa K McIsaac; Kapil Tahlan
Journal:  J Membr Biol       Date:  2017-11-02       Impact factor: 1.843

8.  Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis.

Authors:  Jichan Jang; Ryangyeo Kim; Minjeong Woo; Jinsun Jeong; Da Eun Park; Guehye Kim; Vincent Delorme
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

9.  A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis.

Authors:  Brandon Eilertson; Fernanda Maruri; Amondrea Blackman; Yan Guo; Miguel Herrera; Yuri van der Heijden; Yu Shyr; Timothy R Sterling
Journal:  J Antimicrob Chemother       Date:  2016-06-03       Impact factor: 5.790

Review 10.  DNA Replication in Mycobacterium tuberculosis.

Authors:  Zanele Ditse; Meindert H Lamers; Digby F Warner
Journal:  Microbiol Spectr       Date:  2017-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.